March 6th 2014 FDA approved Aveed for treatment of male hypogonadism, aka testosterone deficiency.1 Aveed is a long-acting form of injectable testosterone called testosterone undecanoate.
The longest study reported to date was conducted by a research group in Germany led by Dr Farid Saad, one of the most prominent worldwide leaders in the field of TRT research. All men received treatment with testosterone undecanoate 1000 mg (Nebido, Bayer Pharma, Berlin, Germany), administered at baseline and at 6 weeks, and thereafter every 12 weeks for up to 72 months. Waist circumference (WC) was measured midpoint between the iliac crest (top of the hip bone) and the lowest rib. All 156 subjects were followed for at least one year, 146 for at least two years, 136 for three years, 114 for four years, 105 for five years, and 69 for six years.
Figure 1 demonstrates the measured reduction in waist circumference subsequent to testosterone therapy in obese diabetic men.
A marked and significant decrease in percentage body weight was noted over the course of testosterone therapy. The mean changes in lipid profiles were gradual and progressive and were significant at each year when compared to baseline levels, reaching plateaus between three and four years.
In addition, testosterone treatment significantly reduced blood pressure, CRP (an inflammatory marker) and levels of the liver enzymes aspartate transaminase (AST) and alanine transaminase (ALT), suggesting a reduction in liver fat content, a reduced inflammatory response, and improvement in liver function. First, this 6-year long study clearly demonstrates that TRT confers long term effects for the duration of treatment. Second, TRT with testosterone undecanoate 1000 mg at baseline, 6 wk and every 12 wk thereafter restored physiological testosterone levels within the first 12 months, and testosterone levels were maintained at this dosage regimen throughout the entire 6-year period.
Third, over the course of 6 years, TRT markedly and significantly reduced total cholesterol and LDL levels, and this reduction was very pronounced and sustained over the entire 6-year period of testosterone treatment. Fourth, another important observation in this study was the marked and significant reduction in triglycerides (blood fats) in response to TRT.
Sixth, it is notable that men with both very low and borderline low total testosterone levels responded equally well to this 6-year long-term testosterone treatment. Finally, this study clearly shows that different outcomes plateau at different time points. Did your doctor tell you that there isn’t enough long-term safety and efficacy data to support the use of TRT? Monica Mollica holds a Master Degree in Nutrition from the University of Stockholm and Karolinska Institue, Sweden. She has also done PhD level course work at renowned Baylor University, TX. Over the entire 6-year observation period, patients lost 15% of their initial body weight (Figure 3). The decrease was significant after one year, further declined after two years (non-significant compared to level after year 1), and then reached a plateau with another slight but statistically significant decrease at five years compared to four years. The decrease in HbA1c was progressive and statistically significant after one year, between two years and one year, between three and two years, between four and three years, and between five and four years and approached significance between six and five years.
It was found that obese diabetic men in the higher testosterone category responded to testosterone treatment equally well as those with lower baseline testosterone levels. This 6-year long TRT study 44 and previous 5-years long studies 3, 4, 6, 7 blatantly refute those claims.
More importantly, TRT not only reduced the levels of total cholesterol and LDL, but also resulted in significant increases in HDL levels. Since intra-abdominal (visceral fat) storage is driven by accumulation of triglycerides, this could help explain the reduction in waist circumference. If so, do yourself a favor and get another doctor who is informed on the latest advances in testosterone research and men’s health. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss.
Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study.
Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). The efficacy and safety of testosterone undecanoate (Nebido((R))) in testosterone deficiency syndrome in Korean: a multicenter prospective study. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM–Nebido). Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. Risk of type 2 diabetes according to traditional and emerging anthropometric indices in Spain, a Mediterranean country with high prevalence of obesity: results from a large-scale prospective cohort study. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis.


Different anthropometric adiposity measures and their association with cardiovascular disease risk factors: a meta-analysis. Comparisons of the strength of associations with future type 2 diabetes risk among anthropometric obesity indicators, including waist-to-height ratio: a meta-analysis.
Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease?
Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Mechanical muscle function and lean body mass during supervised strength training and testosterone therapy in aging men with low-normal testosterone levels. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men.
Testosterone and growth hormone improve body composition and muscle performance in older men. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency.
Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes.
The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial? Onset of effects of testosterone treatment and time span until maximum effects are achieved. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort).
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Trouble is for men considered to have normal levels of Testosterone as they age it is difficult to get the medical profession to prescribe TRT as your levels are not considered abnormal for your age. The reduction in waist circumference was statistically significant at the end of each year compared to the previous year over the first five years, even at the end of six compared to five years. This decrease in body weight was statistically significant at the end of each year compared to the previous year over the first five years, even at the end of six compared to five years. These changes reached a plateau after three years with further slight but not statistically significant decreases. PSA and prostate volume initially rises marginally, but it reaches a plateau at around 12 month (further increase should be related to aging rather than therapy).46 This is a normal response and the initial PSA elevation should not be an indication to discontinue TRT too soon, if there are no contra-indications.
Moreover, the ratio of total cholesterol to HDL cholesterol dropped from over 6 to below 3.5. In addition, the great reduction in triglycerides, especially when combined with the elevation in HDL, is an indication of an increased LDL particle size (i.e.
The aging male : the official journal of the International Society for the Study of the Aging Male. Obesity reviews : an official journal of the International Association for the Study of Obesity.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.
I know that in the UK if I went to my doctor and asked to go on TRT it would probably be refused after tests as they would more than likely come back normal for my age.
Prostate growth is extremely sensitive to variations in androgen concentrations at very low concentrations, but becomes insensitive to changes in androgen concentrations at higher levels.47 A short-term TRT treatment will not allow testosterone saturation of the prostate and PSA to the plateau.
As the total cholesterol to HDL ratio is a risk factor for cardiovascular disease 48, 49, this marked drop is notable. Importantly and interestingly, the reductions in waist circumference and body weight (and percentage change in body weight) were statistically significant at the end of each year compared to the previous year over the first five years, and even at the end of the sixth year compared to fifth year. This is an unusual and remarkable finding, as obesity interventions (both drugs and lifestyle changes) commonly are most effective the first year, and thereafter progressively lose their efficacy.57-59 As this 6-year long study demonstrates, testosterone treatment excels in this regard.
Let’s hope in the near future this information will reach doctors working with patients who are sedentary, obese and suffer from cardio-metabolic complications.




Checking blood sugar one hour after eating should
Normal fasting glucose in nondiabetic adults


Comments

  1. 14.08.2014 at 15:50:17


    She is medically fit, is knowledgeable about controlling body can't filter out the require some type.

    Author: NEQATIF
  2. 14.08.2014 at 21:45:32


    And drink before the test.

    Author: Juliana